eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | intestinal obstruction |
| Comorbidity | C0948303|peritoneal carcinoma |
| Sentences | 8 |
| PubMedID- 24575015 | The synthetic somatostatin analogue lanreotide has shown efficacy in the symptomatic treatment of inoperable bowel obstruction in patients with peritoneal carcinomatosis when administered in the form of microparticles [9]. |
| PubMedID- 24798105 | Recommendations for bowel obstruction with peritoneal carcinomatosis. |
| PubMedID- 22091374 | Malignant small bowel obstruction, as seen in patients with peritoneal carcinomatosis, often of ovarian origin, is a further indication for gastrostomy or gastrojejunostomy as a means of decompression, with a technical success rate in the region of 98% [79]. |
| PubMedID- 24986323 | Surgical management of bowel obstruction in patients with peritoneal carcinomatosis. |
| PubMedID- 23733778 | Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis. |
| PubMedID- 21975697 | Objective: percutaneous endoscopic gastrostomy (peg) tube placement for decompression in advanced peritoneal carcinomatosis with bowel obstruction is a safe and feasible palliative procedure. |
| PubMedID- 25128607 | Re: recommendations for bowel obstruction with peritoneal carcinomatosis by laval et al. |
| PubMedID- 23109694 | Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase iii study. |
Page: 1